Cargando…
Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients
We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical and virologic responses. Three patients h...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495124/ https://www.ncbi.nlm.nih.gov/pubmed/37078720 http://dx.doi.org/10.1093/cid/ciad233 |
| _version_ | 1785104828611952640 |
|---|---|
| author | Haidar, Ghady Jacobs, Jana L Kramer, Kailey Hughes Naqvi, Asma Heaps, Amy Parikh, Urvi McCormick, Kevin D Sobolewski, Michele D Agha, Mounzer Bogdanovich, Tatiana Bushunow, Vasilii Farah, Rafic Hensley, Matthew Hsu, Yen-Michael S Johnson, Bruce Klamar-Blain, Cynthia Kozar, Jennifer Lendermon, Elizabeth Macatangay, Bernard J C Marino, Christopher C Raptis, Anastasios Salese, Erin Silveira, Fernanda P Leen, Ann M Marshall, William L Miller, Michael Patel, Badrish Atillasoy, Ercem Mellors, John W |
| author_facet | Haidar, Ghady Jacobs, Jana L Kramer, Kailey Hughes Naqvi, Asma Heaps, Amy Parikh, Urvi McCormick, Kevin D Sobolewski, Michele D Agha, Mounzer Bogdanovich, Tatiana Bushunow, Vasilii Farah, Rafic Hensley, Matthew Hsu, Yen-Michael S Johnson, Bruce Klamar-Blain, Cynthia Kozar, Jennifer Lendermon, Elizabeth Macatangay, Bernard J C Marino, Christopher C Raptis, Anastasios Salese, Erin Silveira, Fernanda P Leen, Ann M Marshall, William L Miller, Michael Patel, Badrish Atillasoy, Ercem Mellors, John W |
| author_sort | Haidar, Ghady |
| collection | PubMed |
| description | We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical and virologic responses. Three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VSTs in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to 2 courses of remdesivir and experienced sustained recovery after VST administration. The use of VSTs in immunocompromised patients with persistent COVID-19 requires further study. |
| format | Online Article Text |
| id | pubmed-10495124 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104951242023-09-12 Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients Haidar, Ghady Jacobs, Jana L Kramer, Kailey Hughes Naqvi, Asma Heaps, Amy Parikh, Urvi McCormick, Kevin D Sobolewski, Michele D Agha, Mounzer Bogdanovich, Tatiana Bushunow, Vasilii Farah, Rafic Hensley, Matthew Hsu, Yen-Michael S Johnson, Bruce Klamar-Blain, Cynthia Kozar, Jennifer Lendermon, Elizabeth Macatangay, Bernard J C Marino, Christopher C Raptis, Anastasios Salese, Erin Silveira, Fernanda P Leen, Ann M Marshall, William L Miller, Michael Patel, Badrish Atillasoy, Ercem Mellors, John W Clin Infect Dis Brief Report We administered severe acute respiratory syndrome coronavirus-2 viral-specific T cells (VSTs) under emergency investigational new drug applications to 6 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) and characterized clinical and virologic responses. Three patients had partial responses after failing other therapies but then died. Two patients completely recovered, but the role of VSTs in recovery was unclear due to concomitant use of other antivirals. One patient had not responded to 2 courses of remdesivir and experienced sustained recovery after VST administration. The use of VSTs in immunocompromised patients with persistent COVID-19 requires further study. Oxford University Press 2023-04-20 /pmc/articles/PMC10495124/ /pubmed/37078720 http://dx.doi.org/10.1093/cid/ciad233 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Brief Report Haidar, Ghady Jacobs, Jana L Kramer, Kailey Hughes Naqvi, Asma Heaps, Amy Parikh, Urvi McCormick, Kevin D Sobolewski, Michele D Agha, Mounzer Bogdanovich, Tatiana Bushunow, Vasilii Farah, Rafic Hensley, Matthew Hsu, Yen-Michael S Johnson, Bruce Klamar-Blain, Cynthia Kozar, Jennifer Lendermon, Elizabeth Macatangay, Bernard J C Marino, Christopher C Raptis, Anastasios Salese, Erin Silveira, Fernanda P Leen, Ann M Marshall, William L Miller, Michael Patel, Badrish Atillasoy, Ercem Mellors, John W Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients |
| title | Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients |
| title_full | Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients |
| title_fullStr | Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients |
| title_full_unstemmed | Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients |
| title_short | Therapy With Allogeneic Severe Acute Respiratory Syndrome Coronavirus-2–Specific T Cells for Persistent Coronavirus Disease 2019 in Immunocompromised Patients |
| title_sort | therapy with allogeneic severe acute respiratory syndrome coronavirus-2–specific t cells for persistent coronavirus disease 2019 in immunocompromised patients |
| topic | Brief Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495124/ https://www.ncbi.nlm.nih.gov/pubmed/37078720 http://dx.doi.org/10.1093/cid/ciad233 |
| work_keys_str_mv | AT haidarghady therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT jacobsjanal therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT kramerkaileyhughes therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT naqviasma therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT heapsamy therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT parikhurvi therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT mccormickkevind therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT sobolewskimicheled therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT aghamounzer therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT bogdanovichtatiana therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT bushunowvasilii therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT farahrafic therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT hensleymatthew therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT hsuyenmichaels therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT johnsonbruce therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT klamarblaincynthia therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT kozarjennifer therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT lendermonelizabeth therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT macatangaybernardjc therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT marinochristopherc therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT raptisanastasios therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT saleseerin therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT silveirafernandap therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT leenannm therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT marshallwilliaml therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT millermichael therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT patelbadrish therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT atillasoyercem therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients AT mellorsjohnw therapywithallogeneicsevereacuterespiratorysyndromecoronavirus2specifictcellsforpersistentcoronavirusdisease2019inimmunocompromisedpatients |